Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.
Study Type
OBSERVATIONAL
Enrollment
30
Blood test 4 EDTA tubes for biological check-up
Grenoble Alpes University Hospital
La Tronche, France
Comparaison of reduction of concentration of inflammatory cytokines and chemokines in cells treated by oxygen microbubbles vs cells not treated
Validation of inhibition of the production of inflammatory cytokines and chemokines by the monocytes treated by oxygen microbubbles
Time frame: up to 2 years
Comparaison of tissue factor expression at the membrane of monocytes treated by microbubbles vs monocytes not treated
Inhibition of tissue factor expression at the membrane of treated monocytes
Time frame: up to 2 years
Comparaison of glucose metabolism rate in monocytes treated bu microbubbles vs not treated cells
Modulation of glucose metabolism in treated monocytes
Time frame: up to 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.